Breztri Inhaler

Description

Breztri Inhaler
(Budesonide 160 mcg / Glycopyrrolate 4.8 mcg)

Description:
Breztri Inhaler is a combination inhaler used for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). It contains budesonide (160 mcg), a corticosteroid that reduces inflammation in the airways, and glycopyrrolate (4.8 mcg), an anticholinergic (long-acting muscarinic antagonist, LAMA) that helps to relax and open the airways, improving airflow and reducing shortness of breath.

Breztri Inhaler is designed to provide 24-hour relief of COPD symptoms, helping to improve breathing, reduce flare-ups, and prevent further deterioration of lung function. This inhaler is for maintenance therapy and should be used regularly as part of a comprehensive COPD management plan. It is not for the immediate relief of acute COPD symptoms or sudden flare-ups.

Key Features:

• Dual-Action Formula: Combines budesonide (160 mcg), a corticosteroid, to reduce airway inflammation, with glycopyrrolate (4.8 mcg), a LAMA, to help relax and open the airways for improved airflow and reduced shortness of breath.
• 24-Hour Control: Provides consistent, 24-hour symptom control, reducing COPD flare-ups and improving lung function with just one inhalation twice daily.
• Easy-to-Use Inhaler: The Breztri Inhaler is a pressurized metered-dose inhaler (pMDI) designed for ease of use. It delivers a precise dose with each inhalation, making it an effective option for patients who prefer an easy-to-use, portable inhaler for daily use.